secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001641172-25-026316
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference
--------------------------------------------------------------------------------

- Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.
- Presentation at World Lung Cancer Conference in Barcelona, Spain, September 6-9, 2025.
- Primary objective of open-label Phase 1 trial is to evaluate safety and tolerability of the combination.
- ENV105 targets CD105 to reverse drug resistance; also in Phase 2 for castrate-resistant prostate cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225026316/0001641172-25-026316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225026316/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-026316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer